^
BIOMARKER:

Chr del(17p)





Show legend

Include preclinical:
Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma
Multiple Myeloma
Acute Myelogenous Leukemia
Non-Hodgkin’s Lymphoma
Myelodysplastic Syndrome
lenalidomide
obinutuzumab
pembrolizumab
rituximab + alemtuzumab
obinutuzumab + acalabrutinib
duvelisib
ofatumumab
rituximab
venetoclax + rituximab
zanubrutinib
alemtuzumab
rituximab + lenalidomide
idelalisib
pembrolizumab + ibrutinib
nivolumab
DVD
Isa-KRd
T-lymphocyte cell therapy
FCR
Proteasome inhibitor + Immunomodulator
BTK inhibitor
daratumumab
ibrutinib + ublituximab
bortezomib + selinexor
lenalidomide + isatuximab-irfc
lenalidomide + elotuzumab
acalabrutinib
rituximab + idelalisib
venetoclax
ibrutinib
venetoclax + obinutuzumab
LOXO-305
orelabrutinib
venetoclax + ibrutinib
obinutuzumab + zanubrutinib
ibrutinib + lisocabtagene maraleucel
bortezomib
lenalidomide + tafasitamab
idelalisib + ofatumumab
RP6530
ibrutinib + UC-961
selinexor
MGD006
melphalan flufenamide
lenalidomide + ixazomib
azacitidine
thalidomide
MRT68921
Compound C
hydroxychloroquine